| Literature DB >> 23075414 |
Emanuele Carosati1, Anna Tochowicz, Gaetano Marverti, Giambattista Guaitoli, Paolo Benedetti, Stefania Ferrari, Robert M Stroud, Janet Finer-Moore, Rosaria Luciani, Davide Farina, Gabriele Cruciani, M Paola Costi.
Abstract
Human thymidylate synthase (hTS) was targeted through a virtual screening approach. The most optimal inhibitor identified, 2-{4-hydroxy-2-[(2-hydroxybenzylidene)hydrazono]-2,5-dihydrothiazol-5-yl}-N-(3-trifluoromethylphenyl)acetamide (5), showed a mixed-type inhibition pattern, with a K(i) of 1.3 μM and activity against ovarian cancer cell lines with the same potency as cisplatin. X-ray studies revealed that it binds the inactive enzyme conformation. This study is the first example of a nonpeptidic inhibitor that binds the inactive hTS and exhibits anticancer activity against ovarian cancer cells.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23075414 DOI: 10.1021/jm300850v
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446